Irritable Bowel Syndrome Clinical Trial
— IBSOfficial title:
Efficacy of Physiotherapy Techniques on Irritable Bowel Syndrome
Verified date | July 2020 |
Source | IBS Group, Alcalde |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
Introduction and State of Question Irritable Bowel Syndrome can be classified as a functional
digestive disorder characterized by abdominal pain, bloating, and changes in the frequency
and consistency of bowel movements. Recent studies endorse the use of physical therapies for
its symptomatic treatment. With the present study investigators wanted to verify the
effectiveness of physiotherapy techniques in order to alleviate or eliminate the symptoms of
Irritable Bowel Syndrome.
Material and Methods Investigators have carried out an uncontrolled pilot clinical trial in a
sample of 24 patients diagnosed with Irritable Bowel Syndrome in two hospitals in the Region
of Murcia. Among the measurement tools used, we highlight the use of the IBS-Severity Scale,
IBS-QoL, STAI and spirometry tests.
Status | Completed |
Enrollment | 24 |
Est. completion date | June 24, 2020 |
Est. primary completion date | May 30, 2020 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 36 Years to 50 Years |
Eligibility |
Inclusion Criteria: - Over 18 years - Collaborating patients - Patients Diagnosed with IBS from the Digestive System Services of the Virgen de la Arrixaca and Reina Sofía Hospital in Murcia in Outpatient Consultations. - Accept and sign the informed consent - Degree of Severity in the IBS-Severity index from Moderate to Serious (greater than 175p.) - Frequency of abdominal pain in 2 out of 10 days in the IBS-SI Exclusion Criteria: - Patients with fear or phobia of electricity - Restrictive diaphragmatic respiratory pathologies in your medical history, either due to neurological or traumatic causes. - Patients with pacemakers, or diagnosed with heart disease or arrhythmias. - Presence of developing scars, burns, allergies, wounds or infections in the thigh and lower back application areas. - undiagnosed pain - Neoplasms - Deep venous thrombosis - Pregnancy Elimination criteria: - Worsening of symptoms after abdominal massage - Failure to attend sessions of 2 or more days followed by treatment |
Country | Name | City | State |
---|---|---|---|
Spain | Jose Luis Gil Alcalde | Murcia |
Lead Sponsor | Collaborator |
---|---|
IBS Group, Alcalde |
Spain,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | "Change from Baseline IBS-Severity Index at month"- | The severity questionnaire is divided into 3 sections. The first is the main one, and collects information about the severity. It contains 4 questions, each with a maximum score of 100 using visual analog scales, out of a maximum score of 500. | "up to four weeks" | |
Primary | "Change from Baseline IBS-QoL score at month"- | It is a self-administered questionnaire, which is usually answered in about 10 min. This consists of 34 items with a value of 5 points each, which collect information on the quality of life of patients affected with IBS. This questionnaire is classified into 8 main areas: dysphoria, interference with activity, body image, health concern, avoidance of food, social relationships, sexual scale and relationships. | "up to four weeks" | |
Primary | "Change from Baseline Trait Anxiety Inventory (STAI) score at month" | It is divided into two subscales (AE and AR). The AE scale consists of 20 sentences that the subject scores from 0 to 3 and defines how he feels in a "specific moment". Trait anxiety (AR) signals an anxious predisposition to perceive situations as threatening. The AR scale consists of 20 sentences, shows how the subject feels in "general". | "up to four weeks" | |
Primary | "Change from Baseline Simple spirometry parameters at month" | It is a diagnostic test that allows the detection of respiratory pathologies of an obstructive or restrictive nature, as well as making a differential diagnosis in patients at risk. This device allows investigator to measure the following parameters: Forced Vital Capacity (FVC), Forced Expiration Volume in one second (FEV1), calculate the Tifenneau Index of the examinee by means of the ratio between FEV1 and FVC. It also allows to measure the Peak of Maximum Expiratory Flow (PEF), 25% of FVC flow (FEF25), among others possible.The measurement of these parameters will be carried out with the help of the CONTEC SP10W digital spirometer, with a European Conformity certificate (CE-0123). Electromagnetic Compatibility (EMC): Group I, class B. ¾ Class B (Electromagnetic system, which is marketed for use in a residential environment. Its limits are stricter than industrial devices). Medical devices - covered by directive, 93/42 / EEC. Classification of medical device IIa. | "up to four weeks" | |
Secondary | "Change from Baseline Setpoint Abdominal Pain in IBS-Severity Index at month" | Setpoint of the severity scale that measures the subjective sensation of abdominal pain with a visual scale. | "up to four weeks" | |
Secondary | "Change from Baseline Setpoint funcional bloating in IBS-Severity Index at month" | Setpoint of the severity scale that measures the subjective sensation of bloating | "up to four weeks" | |
Secondary | "Change from baseline of bowel movements at month" | Maximum number of bowel movements in one week | "up to four weeks" |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT03720314 -
Microbiota Profiling in IBS
|
||
Recruiting |
NCT06166563 -
Exercise, Irritable Bowel Syndrome and Fibromyalgia
|
N/A | |
Completed |
NCT05213910 -
Study of a Management Strategy of Functional Bowel Disordes Related to Irritable Bowel Syndrome (IBS) With a Mixture of 8 Microbiotic Strains
|
N/A | |
Recruiting |
NCT05985018 -
Traditional Dietary Advice Vs. Mediterranean Diet in IBS
|
N/A | |
Completed |
NCT06407609 -
Positive Outcomes of the Supplementation With Lecithin-based Delivery Form of Curcuma Longa and of Boswellia Serrata in IBS
|
N/A | |
Completed |
NCT04656730 -
Effect of STW5 (Iberogast ®) and STW5-II (Iberogast N®) on Transit and Tolerance of Intestinal Gas
|
Phase 4 | |
Completed |
NCT04145856 -
Combination of Alverine-simeticone and i3.1 Probiotic in IBS-D and IBS-M in Mexico
|
Phase 4 | |
Recruiting |
NCT04138225 -
The Ecological Role of Yeasts in the Human Gut
|
||
Active, not recruiting |
NCT03586622 -
One Year Home Monitoring and Treatment of IBS Patients
|
N/A | |
Completed |
NCT05207618 -
Utility of the Administration of Chesnut and Quebracho Extract for Irritable Bowel Syndrome Diarrhea Predominant
|
N/A | |
Not yet recruiting |
NCT06369753 -
Visible Abdominal Distension
|
N/A | |
Not yet recruiting |
NCT05157867 -
In Vivo Effects of Amylase Trypsin Inhibitors
|
N/A | |
Not yet recruiting |
NCT05100719 -
The Role of Irritable Bowel Syndrome in Lactose Intolerance (LION)
|
N/A | |
Recruiting |
NCT05001997 -
Effects of Lactose-free Dairy Products on Athletes With Irritable Bowel Syndrome
|
N/A | |
Recruiting |
NCT02953171 -
Probiotics in the Treatment of Irritable Bowel Syndrome
|
N/A | |
Completed |
NCT02977975 -
Lacto-fermented Sauerkraut in the Treatment of Irritable Bowel Syndrome
|
N/A | |
Completed |
NCT03266068 -
Epidemiology and Pathophysiology of Post-Infectious Functional GI Disorders
|
||
Completed |
NCT02980406 -
The Role of FODMAPs in Upper GI Effects, Colonic Motor Activity and Gut-brain Signaling at the Behavioral Level
|
N/A | |
Completed |
NCT03318614 -
Bifidobacterium Infantis M-63 Improves Mental Health in Irritable Bowel Syndrome Developed After a Major Flood Disaster
|
Phase 2/Phase 3 | |
Recruiting |
NCT02242175 -
Efficacy of Hydrogen Breath Test in the Patients With Irritable Bowel Syndrome
|
N/A |